{"timestamp": "2026-01-18T00:15:56.057185", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"TC 6 cycles\"]},\"BIOMARKERS\":{\"AFP\":\"Unknown\",\"CA125\":\"21827 (2025-06-18)\",\"HER2\":\"0\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Wildtype\",\"BRCA2\":\"Wildtype\",\"CURRENT_STATUS\":\"PD (2025-02-21)\",\"DIAGNOSIS\":{\"components\":[\"poorly differentiated carcinoma\",\"treatment effect\"],\"histology\":\"倾向高级别浆液性癌\",\"laterality\":\"Bilateral\",\"primary\":\"Recurrent ovarian cancer\",\"site\":\"Ovary\"},\"HRD\":\"Negative\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"cycles\":\"2\",\"end_date\":\"2020-10-14\",\"intent\":\"Adjuvant\",\"line\":\"Unknown\",\"regimen\":\"术前顺铂+多西他赛 (2 cycles, neoadjuvant)\",\"start_date\":\"Unknown\"},{\"cycles\":\"6\",\"end_date\":\"2021-08\",\"intent\":\"Adjuvant\",\"line\":\"1L\",\"regimen\":\"TC 6 cycles\",\"start_date\":\"Unknown\"},{\"cycles\":\"Unknown\",\"end_date\":\"2022-12\",\"intent\":\"Unknown\",\"line\":\"Maintenance\",\"regimen\":\"尼拉维持\",\"start_date\":\"Unknown\"},{\"cycles\":\"6\",\"end_date\":\"2023-11-22\",\"intent\":\"Salvage\",\"line\":\"2L\",\"regimen\":\"Post-op TC 6 cycles (4th cycle added 贝伐)\",\"start_date\":\"2023-04\"},{\"cycles\":\"Unknown\",\"end_date\":\"2024-03-13\",\"intent\":\"Palliative\",\"line\":\"3L\",\"regimen\":\"依托泊苷+艾坦\",\"start_date\":\"2024-01-03\"},{\"cycles\":\"4+\",\"end_date\":\"2024-08-27\",\"intent\":\"Palliative\",\"line\":\"3L\",\"regimen\":\"顺铂+多美素\",\"start_date\":\"2024-03-27\"},{\"cycles\":\"3\",\"end_date\":\"2025-02-21\",\"intent\":\"Palliative\",\"line\":\"4L+\",\"regimen\":\"白蛋白紫杉醇100mg/m2 d1,8,15 + 贝伐珠单抗5mg/kg d1,15\",\"start_date\":\"2025-02-21\"},{\"cycles\":\"1\",\"end_date\":\"2025-05-09\",\"intent\":\"Palliative\",\"line\":\"4L+\",\"regimen\":\"多西他赛+奥沙利铂\",\"start_date\":\"2025-05-09\"}],\"MAINTENANCE\":\"Yes\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Yes\",\"regimens\":[\"尼拉维持\",\"贝伐维持\"],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Yes\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2021-08\",\"evidence\":\"Recurrence requiring second surgery in 2023-04\",\"evidence_type\":\"Clinical\",\"first_relapse_date\":\"2023-04\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Unknown\"},{\"PFI_days\":\"42\",\"end_date\":\"2023-11-22\",\"evidence\":\"Start of subsequent systemic therapy (依托泊苷+艾坦) on 2024-01-03\",\"evidence_type\":\"Clinical\",\"first_relapse_date\":\"2024-01-03\",\"line\":\"2L\",\"start_date\":\"2023-04\",\"status\":\"Resistant\"},{\"PFI_days\":\"48\",\"end_date\":\"2024-08-27\",\"evidence\":\"CA125 3119.8 on 2024-10-14\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2024-10-14\",\"line\":\"3L\",\"start_date\":\"2024-03-27\",\"status\":\"Resistant\"},{\"PFI_days\":\"40\",\"end_date\":\"2025-05-09\",\"evidence\":\"CA125 21827 on 2025-06-18\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2025-06-18\",\"line\":\"4L+\",\"start_date\":\"2025-05-09\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"40\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2025-06-18\",\"evidence\":\"CA125 21827\",\"type\":\"Biochemical\"},\"STAGE\":{\"stage_basis\":\"Pathology\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2020-10-14\",\"performed\":\"Yes\",\"procedure\":\"Radical ovarian cancer surgery + debulking + intraperitoneal hyperthermic perfusion catheter placement\"},\"VISIT_DATE\":\"2023-07-01\",\"first_relapse_date\":\"2023-04\",\"last_platinum_end_date\":\"2025-05-09\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2023-11\",\"flag\":\"↑\",\"value\":\"200+\"},{\"date\":\"2024-03-21\",\"flag\":\"↑\",\"value\":\"10000\"},{\"date\":\"2024-07-26\",\"flag\":\"↑\",\"value\":\"5400\"},{\"date\":\"2024-08-26\",\"flag\":\"↑\",\"value\":\"4153.29\"},{\"date\":\"2024-10-14\",\"flag\":\"↑\",\"value\":\"3119.8\"},{\"date\":\"2025-02-21\",\"flag\":\"↑\",\"value\":\"5768\"},{\"date\":\"2025-03-12\",\"flag\":\"↑\",\"value\":\"3643\"},{\"date\":\"2025-04-28\",\"flag\":\"↑\",\"value\":\"12287\"},{\"date\":\"2025-06-18\",\"flag\":\"↑\",\"value\":\"21827\"}],\"latest\":{\"date\":\"2025-06-18\",\"flag\":\"↑\",\"value\":\"21827\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"}],\"milestones\":[{\"date\":\"2020-10-14\",\"description\":\"Initial radical surgery\",\"type\":\"Surgery\"},{\"date\":\"2021-08\",\"description\":\"Completion of adjuvant TC\",\"type\":\"ChemoEnd\"},{\"date\":\"2023-04\",\"description\":\"Second surgery for recurrence\",\"type\":\"Relapse\"},{\"date\":\"2025-05-09\",\"description\":\"多西他赛+奥沙利铂 given (1 cycle)\",\"type\":\"ChemoStart\"},{\"date\":\"2025-06-18\",\"description\":\"Marked CA125 rise\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"1 cycle\",\"last_admin_date\":\"2025-05-09\",\"name\":\"多西他赛+奥沙利铂\"},\"genetic_testing\":{\"germline\":[\"HRD: Negative\",\"BRCA1: Wildtype\",\"BRCA2: Wildtype\"],\"somatic\":[\"HRD: Negative\",\"BRCA1: Wildtype\",\"BRCA2: Wildtype\"]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"术前顺铂+多西他赛\",\"TC\",\"尼拉维持\",\"Post-op TC (2023) + 贝伐 from cycle 4\",\"依托泊苷+艾坦\",\"顺铂+多美素\",\"白蛋白紫杉醇100mg/m2 d1,8,15 + 贝伐珠单抗5mg/kg d1,15\",\"多西他赛+奥沙利铂\"]},\"NUC_MED\":{\"studies\":[{\"avid_lesions\":[],\"confidence\":\"Moderate\",\"date\":\"2023-12\",\"non_avid_notes\":[\"No abnormality on PET\"],\"type\":\"FDG-PET/CT\"}]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"低分化癌\",\"treatment effect\"],\"date\":\"Unknown\",\"diagnosis\":\"低分化癌，依据HE形态，倾向高级别浆液性癌\",\"grade\":\"Low differentiated\",\"ihc\":[{\"marker\":\"PAX8\",\"result\":\"+\"},{\"marker\":\"P53\",\"result\":\"+\"},{\"marker\":\"WT1\",\"result\":\"+\"},{\"marker\":\"CDX2-88\",\"result\":\"-\"},{\"marker\":\"HER2\",\"result\":\"0\"}],\"involvement_sites\":[\"right and left diaphragm\",\"mesentery of ileocecal region\",\"rectouterine pouch\",\"greater omentum\",\"hepatorenal recess\",\"left pelvic wall\",\"sigmoid mesocolon surface\",\"left paracolic gutter\",\"right paracolic gutter\",\"appendix serosa and muscular wall\",\"uterine serosa (anterior wall)\",\"gastric pylorus and gastroepiploic lymph node (1/2 positive)\",\"left liver nodule (free epithelial cells noted)\"],\"laterality\":\"Bilateral\",\"molecular\":[{\"result\":\"胚系-，体系BRCA ETV4 KMT2A NF1 TP53突变\",\"test\":\"Panel\"}],\"raw_text\":\"本院病理会诊咨询意见:（双附件）双侧卵巢表面、双侧输卵管黏膜面及浆膜面均见低分化癌，灶区间质伴治疗后改变，依据HE形态，倾向高级别浆液性癌。（子宫）肌壁间平滑肌瘤；内膜呈萎缩性改变；宫颈慢性炎；子宫前壁浆膜面见癌累及。（右侧隔肌、左侧隔肌、回盲部系膜、子宫直肠窝、大网膜、肝肾隐窝、左侧盆壁、乙状结肠系膜表面、左结肠旁沟、右结肠旁沟）均见癌累及。（阑尾）慢性炎，浆膜面及肌壁见癌累及。本院病理会诊咨询意见:1、（胃幽门周围，胃网膜弓淋巴结）淋巴结（1/2）见癌转移。2、（左肝结节）肝组织，部分区肝窦扩张充血，另见少量游离的核大深染的上皮细胞。补充诊断1：补充报告:病理会诊咨询意见:1、（胃幽门周围，胃网膜弓淋巴结）淋巴结（1/2）见癌转移，结合免疫组化结果，首先考虑为高级别浆液性癌，请结合临床首先查女性生殖系统。2、（左肝结节）肝组织，部分区肝窦扩张充血，另见少量游离的核大深染的上皮细胞。免疫组化结果：肿瘤细胞 PAX8（+），P53（+），WT1（+），CDX2-88（-），HER2（0）\",\"sample_type\":\"Surgical specimen\",\"site\":\"Bilateral adnexa, fallopian tubes, uterus, peritoneal surfaces, appendix, lymph nodes, liver nodule\",\"tumor_size\":\"Unknown\",\"uncertainty_or_missing\":[\"exact pathology report date not provided\",\"tumor sizes not specified\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"abdomen\"],\"date\":\"2025-06-28\",\"findings\":[\"abdominal cystic lesion, possible pseudomyxoma\",\"slight low-density hepatic nodules\",\"right renal mild hydronephrosis\"],\"impression\":\"Abdominal cystic lesions possibly pseudomyxoma; hepatic low-density nodules; right mild hydronephrosis\",\"modality\":\"CT\",\"trend_vs_prior\":\"Unknown\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2020-10-14\",\"description\":\"Radical ovarian cancer surgery + debulking + intraperitoneal hyperthermic perfusion catheter placement at outside hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Postoperative pathology: 高浆\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08\",\"description\":\"Completion of postoperative TC 6 cycles (adjuvant)\",\"event_type\":\"Chemo\",\"key_result\":\"Last adjuvant chemo 2021-08\",\"regimen_or_test\":\"TC\"},{\"date\":\"2022-12\",\"description\":\"Last dose of maintenance 尼拉维持\",\"event_type\":\"Chemo\",\"key_result\":\"Last dose 2022-12\",\"regimen_or_test\":\"尼拉维持\"},{\"date\":\"2023-04\",\"description\":\"Second surgery for recurrence at outside hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Post-op TC 6 cycles planned\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2023-11-22\",\"description\":\"Completion of postoperative TC 6 cycles (second surgery adjuvant), bevacizumab added from cycle 4\",\"event_type\":\"Chemo\",\"key_result\":\"Last dose 2023-11-22\",\"regimen_or_test\":\"TC + 贝伐\"},{\"date\":\"2023-11\",\"description\":\"CA125 elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA125 >200\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2023-12\",\"description\":\"FDG-PET at outside hospital\",\"event_type\":\"Other\",\"key_result\":\"No abnormality\",\"regimen_or_test\":\"PET\"},{\"date\":\"2024-01-03\",\"description\":\"Start 依托泊苷+艾坦 for recurrence\",\"event_type\":\"Chemo\",\"key_result\":\"Start date 2024-01-03\",\"regimen_or_test\":\"依托泊苷+艾坦\"},{\"date\":\"2024-03-13\",\"description\":\"Last dose of 依托泊苷+艾坦\",\"event_type\":\"Chemo\",\"key_result\":\"Last dose 2024-03-13\",\"regimen_or_test\":\"依托泊苷+艾坦\"},{\"date\":\"2024-03-27\",\"description\":\"Start 顺铂+多美素 (3 cycles then continued with bev addition)\",\"event_type\":\"Chemo\",\"key_result\":\"Start date 2024-03-27\",\"regimen_or_test\":\"顺铂+多美素\"},{\"date\":\"2024-07-01\",\"description\":\"After 3 cycles of 顺铂+多美素, last of initial 3 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Last of first 3 cycles 2024-07-01\",\"regimen_or_test\":\"顺铂+多美素\"},{\"date\":\"2024-07-26\",\"description\":\"CA125 measurement at outside hospital\",\"event_type\":\"Lab\",\"key_result\":\"CA125 5400\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2024-08-26\",\"description\":\"CA125 during bevacizumab maintenance\",\"event_type\":\"Lab\",\"key_result\":\"CA125 4153.29\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2024-08-27\",\"description\":\"Last administration of 4th cycle with added bevacizumab\",\"event_type\":\"Chemo\",\"key_result\":\"Last dose 2024-08-27\",\"regimen_or_test\":\"顺铂+多美素 + 贝伐\"},{\"date\":\"2024-10-14\",\"description\":\"CA125 measured at outside hospital\",\"event_type\":\"Lab\",\"key_result\":\"CA125 3119.8\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2025-02-21\",\"description\":\"白蛋白紫杉醇100mg/m2 d1,8,15 + 贝伐珠单抗5mg/kg d1,15 given *3; last dose 2025-02-21; PD noted\",\"event_type\":\"Chemo\",\"key_result\":\"PD; CA125 5768\",\"regimen_or_test\":\"白蛋白紫杉醇 + 贝伐珠单抗\"},{\"date\":\"2025-03-12\",\"description\":\"CA125 measurement\",\"event_type\":\"Lab\",\"key_result\":\"CA125 3643\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2025-03-31\",\"description\":\"Screening biochemistry: creatinine 86 umol/l (weight 51kg, CrCl 53 mL/min)\",\"event_type\":\"Lab\",\"key_result\":\"Did not meet trial inclusion\",\"regimen_or_test\":\"Chemistry\"},{\"date\":\"2025-04-07\",\"description\":\"Registered as screening failure for trial GH2616C102\",\"event_type\":\"Other\",\"key_result\":\"Screening failed 2025-04-07\",\"regimen_or_test\":\"Trial screening\"},{\"date\":\"2025-04-28\",\"description\":\"Tumor markers measured\",\"event_type\":\"Lab\",\"key_result\":\"CA125 12287, CA199 2920\",\"regimen_or_test\":\"CA125 / CA19-9\"},{\"date\":\"2025-05-09\",\"description\":\"多西他赛+奥沙利铂 1 cycle given then chemotherapy paused for bowel obstruction\",\"event_type\":\"Chemo\",\"key_result\":\"1 cycle given 2025-05-09\",\"regimen_or_test\":\"多西他赛+奥沙利铂\"},{\"date\":\"2025-06-18\",\"description\":\"CA125 markedly elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA125 21827\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2025-06-28\",\"description\":\"Outside CT: abdominal cystic lesion, possible pseudomyxoma; slight low-density hepatic nodules; right renal mild hydronephrosis\",\"event_type\":\"Imaging\",\"key_result\":\"Findings as above\",\"regimen_or_test\":\"CT abdomen\"}]}}", "final_output": "- If ECOG ≥3 or refractory bowel obstruction, then adjust management from systemic therapy to best supportive/palliative-focused care.  \n\n- If imaging confirms extensive pseudomyxoma-like peritoneal disease without resectability, then adjust management from cytoreductive intent to symptom-directed systemic/supportive care.  \n\n- If CT/MRI or PET shows oligometastatic, potentially resectable lesions, then adjust management from systemic-only to consider surgical/locoregional MDT.  \n\n- If creatinine clearance falls <40 mL/min or major organ dysfunction emerges, then adjust management from full-dose multiagent therapy to modified/less intensive regimens.  \n\n- If patient prioritizes quality of life over survival extension, then adjust management from aggressive multi-line chemotherapy to minimal-burden palliative and hospice-focused approach.", "initial_ops": {"chair": "- Today’s intent: disease is platinum‑resistant, heavily pretreated; shift focus toward symptom‑driven, QoL‑prioritized palliative strategy.  \n- Before new systemic therapy: update ECOG, organ function (full labs, CrCl, liver tests), pain/ascites status, bowel obstruction details.  \n- Clarify current symptoms from abdominal cysts, hydronephrosis, possible obstruction to prioritize surgery/intervention, stenting, drainage versus systemic therapy.  \n- Reassess clinical‑trial eligibility (non‑platinum, non‑PARPi options) given HRD‑negative, BRCA‑wildtype, prior PARPi/anti‑VEGF exposure.  \n- Early palliative care involvement for analgesia, bowel management, nutrition, and to align treatment intensity with patient/family goals.", "oncologist": "- Heavily pretreated recurrent high-grade serous ovarian carcinoma with progression on multiple platinum and non-platinum regimens; current line ≥5L.  \n\n- Recent sharp CA125 rise (21827, 2025-06-18) indicating biochemical progression after short-lived response to latest chemotherapy.  \n\n- Prior PARP inhibitor maintenance and prior anti-VEGF exposure limit expected benefit of reusing these targeted strategies.  \n\n- HRD and germline/somatic BRCA wildtype reduce rationale for further PARP inhibitor–based approaches.  \n\n- Missing: current ECOG/performance, detailed organ function (CBC, renal, hepatic), symptom burden/imaging to distinguish systemic therapy vs best supportive focus.", "radiologist": "- Large abdominal cystic lesions concerning for pseudomyxoma peritonei; size, exact distribution, and organ involvement need dedicated contrast CT report update. [@IMAGING_STUDIES|2025-06-28]\n\n- Multiple low-density hepatic nodules could represent metastases; require characterization with contrast-enhanced liver protocol CT or MRI. [@IMAGING_STUDIES|2025-06-28]\n\n- Mild right hydronephrosis suggests partial urinary tract obstruction; upstream ureteral level and cause need dedicated abdominopelvic imaging description. [@IMAGING_STUDIES|2025-06-28]\n\n- Disease trend versus prior imaging is unknown; require prior CT/MRI for comparison to assess progression or stability. [unknown/needs update]\n\n- PET/CT showed no abnormal FDG-avid disease in 2023; interval metabolic status since then is unknown. [@PET_IF_AVAILABLE|2023-12]", "pathologist": "- Histology and IHC support high-grade serous carcinoma of tubo-ovarian origin involving widespread peritoneal surfaces and nodes [@CASE_VIEW|Unknown].  \n\n- Pathology shows low differentiation; formal FIGO stage not provided but distribution suggests advanced stage disease [@CASE_VIEW|Unknown].  \n\n- Somatic panel: HRD negative, BRCA1/2 wildtype; other mutations reported (ETV4, KMT2A, NF1, TP53) [@CASE_VIEW|Unknown].  \n\n- Biomarkers: PAX8+, WT1+, aberrant p53+, HER2 0; MSI, TMB, PD-L1 not reported [@CASE_VIEW|Unknown].  \n\n- Needed updates: exact pathology report dates, tumor sizes, FIGO stage assignment, full molecular report details (including MSI/TMB/PD-L1).", "nuclear": "- Prior FDG-PET/CT showed no hypermetabolic disease; no PET-visible metastases or recurrence at that time [@PET_CT|2023-12].  \n- Current CT describes abdominal cystic lesions and hepatic nodules, but their FDG avidity is unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \n- Right mild hydronephrosis is noted structurally; metabolic correlate on PET is unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \n- A repeat FDG-PET/CT could clarify metabolic activity of abdominal/hepatic lesions and up-/down-stage disease versus 2023 baseline.  \n- PET would meaningfully change suspicion of recurrence if new focal uptake appears in cystic, hepatic, or urinary-tract–adjacent regions."}, "merged_summary": "Key Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.", "final_round_ops": {"Round 1": {"chair": "- Confirm current symptoms, ECOG, renal/hepatic function, bowel obstruction status; many parameters unknown and critical for further therapy choices.  \n\n- Given multi-line platinum-resistant course and rising CA125 21827 [@CASE_CORE|2025-06-18], prioritize goals-of-care and quality-of-life discussion.  \n\n- Obtain updated cross-sectional imaging and review possible pseudomyxoma, hepatic nodules, hydronephrosis [@RADIOLOGY|2025-06-28] to define disease burden and complications.  \n\n- Systemic anti-cancer options should be considered only after MDT review of organ function, prior toxicities, and patient preferences; regimen unspecified.  \n\n- Ensure early palliative-care involvement for pain, ascites, bowel/urinary issues; adjust plan dynamically as new labs and imaging return.", "oncologist": "- Prioritize goals‑of‑care discussion, documenting ECOG, detailed symptoms, and patient preferences to guide further systemic versus supportive care (currently unknown).  \n\n- Obtain updated labs (CBC, renal incl. CrCl, liver, electrolytes, nutrition) to assess fitness and safety for any further systemic therapy (currently unknown).  \n\n- Arrange contrast‑enhanced CT abdomen/pelvis and compare to prior imaging to characterize cystic disease, liver nodules, and hydronephrosis (details unknown).  \n\n- Convene MDT with surgery, interventional radiology, urology, and palliative care to plan symptom‑targeted procedures (drainage, obstruction relief, urinary decompression).  \n\n- Reassess non‑platinum, non‑PARPi systemic or clinical trial options only if performance status, labs, and patient goals support further treatment.", "radiologist": "- Large abdominal cystic lesions (possible pseudomyxoma) need contrast CT abdomen/pelvis with mapping for potential drainage or debulking planning. [@IMAGING_STUDIES|2025-06-28]\n\n- Low‑density hepatic nodules require contrast-enhanced liver imaging (CT/MRI) to confirm metastases versus benign lesions, if findings would alter palliation. [@IMAGING_STUDIES|2025-06-28]\n\n- Mild right hydronephrosis warrants definition of ureteric obstruction level and cause on contrast CT to guide stent/nephrostomy consideration. [@IMAGING_STUDIES|2025-06-28]\n\n- Disease trend is unknown; comparison with prior CT/MRI is needed only if it would influence symptom‑directed interventions. [unknown/needs update]\n\n- Repeat PET/CT is not routinely indicated; reserve for situations where additional metabolic information would clearly change local vs systemic strategy. [@PET_IF_AVAILABLE|2023-12]", "pathologist": "- Confirm no additional pathology/molecular reports (FIGO stage, MSI, TMB, PD‑L1, full panel dates) from outside institutions; currently unknown.  \n\n- Maintain diagnosis: recurrent high‑grade serous tubo‑ovarian carcinoma, low differentiated, BRCA/HRD wildtype, HER2 0 [@CASE_VIEW|Unknown].  \n\n- Document somatic mutations (ETV4, KMT2A, NF1, TP53) and HRD–/BRCA WT status clearly in the MDT record [@CASE_VIEW|Unknown].  \n\n- Reserve new biomarker testing (MSI/TMB/PD‑L1) for situations where results could realistically change palliative‑oriented management; presently unknown.  \n\n- No histologic evidence of alternative primary (e.g., gastrointestinal); PAX8+/WT1+/p53+ profile supports Müllerian origin [@CASE_VIEW|Unknown].", "nuclear": "- Prior FDG-PET/CT showed no hypermetabolic disease; no PET-detectable metastases or recurrence at that time [@PET_CT|2023-12].  \n- Current abdominal cystic lesions, hepatic nodules, and hydronephrosis lack PET correlation; metabolic activity remains unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \n- In this palliative context, repeat PET/CT is only justified if results would clearly change local versus systemic management decisions.  \n- PET would meaningfully upstage suspicion of recurrence if new focal FDG uptake appears in cystic, hepatic, or retroperitoneal regions.  \n- If future interventions are planned, consider PET/CT to distinguish metabolically active tumor from non-neoplastic cystic or treatment-related changes."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": "Systemic‑therapy decision requires contemporaneous ECOG, symptom burden, and full labs (CBC, renal, liver, nutrition); without these we cannot meaningfully weigh further chemotherapy versus best‑supportive‑care focus.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": "Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered.", "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.", "oncologist": "Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Today’s intent: disease is platinum‑resistant, heavily pretreated; shift focus toward symptom‑driven, QoL‑prioritized palliative strategy.  \n- Before new systemic therapy: update ECOG, organ function (full labs, CrCl, liver tests), pain/ascites status, bowel obstruction details.  \n- Clarify current symptoms from abdominal cysts, hydronephrosis, possible obstruction to prioritize surgery/intervention, stenting, drainage versus systemic therapy.  \n- Reassess clinical‑trial eligibility (non‑platinum, non‑PARPi options) given HRD‑negative, BRCA‑wildtype, prior PARPi/anti‑VEGF exposure.  \n- Early palliative care involvement for analgesia, bowel management, nutrition, and to align treatment intensity with patient/family goals.", "timestamp": "2026-01-18T00:14:20.347922"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"target\":\"med_onc\",\"message\":\"当前为高度多线治疗后的铂耐药、高肿瘤负荷并疑肠道受累阶段，建议本次不要立即再启用细胞毒化疗，而是先由内外科/营养/姑息多学科评估肠梗阻风险、营养状态和肾功能，明确是否还有任何化疗或临床试验获益空间，或应尽早转换以症状控制为主的最佳支持治疗路径。\",\"why\":\"safety|missing\"}", "timestamp": "2026-01-18T00:14:46.765927"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "- Need clarification: visit date is 2023-07-01 but data include events through 2025-06; which timeframe should guide today’s decision?  \n- Current status (bowel obstruction, performance status, symptoms, goals of care) and full labs/renal function are missing and essential before new systemic plan.", "timestamp": "2026-01-18T00:14:59.965305"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Confirm current symptoms, ECOG, renal/hepatic function, bowel obstruction status; many parameters unknown and critical for further therapy choices.  \n\n- Given multi-line platinum-resistant course and rising CA125 21827 [@CASE_CORE|2025-06-18], prioritize goals-of-care and quality-of-life discussion.  \n\n- Obtain updated cross-sectional imaging and review possible pseudomyxoma, hepatic nodules, hydronephrosis [@RADIOLOGY|2025-06-28] to define disease burden and complications.  \n\n- Systemic anti-cancer options should be considered only after MDT review of organ function, prior toxicities, and patient preferences; regimen unspecified.  \n\n- Ensure early palliative-care involvement for pain, ascites, bowel/urinary issues; adjust plan dynamically as new labs and imaging return.", "timestamp": "2026-01-18T00:15:24.566205"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-07-01 15:38:50.183000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Confirm current symptoms, ECOG, renal/hepatic function, bowel obstruction status; many parameters unknown and critical for further therapy choices.  \\n\\n- Given multi-line platinum-resistant course and rising CA125 21827 [@CASE_CORE|2025-06-18], prioritize goals-of-care and quality-of-life discussion.  \\n\\n- Obtain updated cross-sectional imaging and review possible pseudomyxoma, hepatic nodules, hydronephrosis [@RADIOLOGY|2025-06-28] to define disease burden and complications.  \\n\\n- Systemic anti-cancer options should be considered only after MDT review of organ function, prior toxicities, and patient preferences; regimen unspecified.  \\n\\n- Ensure early palliative-care involvement for pain, ascites, bowel/urinary issues; adjust plan dynamically as new labs and imaging return.\",\n    \"oncologist\": \"- Prioritize goals‑of‑care discussion, documenting ECOG, detailed symptoms, and patient preferences to guide further systemic versus supportive care (currently unknown).  \\n\\n- Obtain updated labs (CBC, renal incl. CrCl, liver, electrolytes, nutrition) to assess fitness and safety for any further systemic therapy (currently unknown).  \\n\\n- Arrange contrast‑enhanced CT abdomen/pelvis and compare to prior imaging to characterize cystic disease, liver nodules, and hydronephrosis (details unknown).  \\n\\n- Convene MDT with surgery, interventional radiology, urology, and palliative care to plan symptom‑targeted procedures (drainage, obstruction relief, urinary decompression).  \\n\\n- Reassess non‑platinum, non‑PARPi systemic or clinical trial options only if performance status, labs, and patient goals support further treatment.\",\n    \"radiologist\": \"- Large abdominal cystic lesions (possible pseudomyxoma) need contrast CT abdomen/pelvis with mapping for potential drainage or debulking planning. [@IMAGING_STUDIES|2025-06-28]\\n\\n- Low‑density hepatic nodules require contrast-enhanced liver imaging (CT/MRI) to confirm metastases versus benign lesions, if findings would alter palliation. [@IMAGING_STUDIES|2025-06-28]\\n\\n- Mild right hydronephrosis warrants definition of ureteric obstruction level and cause on contrast CT to guide stent/nephrostomy consideration. [@IMAGING_STUDIES|2025-06-28]\\n\\n- Disease trend is unknown; comparison with prior CT/MRI is needed only if it would influence symptom‑directed interventions. [unknown/needs update]\\n\\n- Repeat PET/CT is not routinely indicated; reserve for situations where additional metabolic information would clearly change local vs systemic strategy. [@PET_IF_AVAILABLE|2023-12]\",\n    \"pathologist\": \"- Confirm no additional pathology/molecular reports (FIGO stage, MSI, TMB, PD‑L1, full panel dates) from outside institutions; currently unknown.  \\n\\n- Maintain diagnosis: recurrent high‑grade serous tubo‑ovarian carcinoma, low differentiated, BRCA/HRD wildtype, HER2 0 [@CASE_VIEW|Unknown].  \\n\\n- Document somatic mutations (ETV4, KMT2A, NF1, TP53) and HRD–/BRCA WT status clearly in the MDT record [@CASE_VIEW|Unknown].  \\n\\n- Reserve new biomarker testing (MSI/TMB/PD‑L1) for situations where results could realistically change palliative‑oriented management; presently unknown.  \\n\\n- No histologic evidence of alternative primary (e.g., gastrointestinal); PAX8+/WT1+/p53+ profile supports Müllerian origin [@CASE_VIEW|Unknown].\",\n    \"nuclear\": \"- Prior FDG-PET/CT showed no hypermetabolic disease; no PET-detectable metastases or recurrence at that time [@PET_CT|2023-12].  \\n- Current abdominal cystic lesions, hepatic nodules, and hydronephrosis lack PET correlation; metabolic activity remains unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \\n- In this palliative context, repeat PET/CT is only justified if results would clearly change local versus systemic management decisions.  \\n- PET would meaningfully upstage suspicion of recurrence if new focal FDG uptake appears in cystic, hepatic, or retroperitoneal regions.  \\n- If future interventions are planned, consider PET/CT to distinguish metabolically active tumor from non-neoplastic cystic or treatment-related changes.\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "- If ECOG ≥3 or refractory bowel obstruction, then adjust management from systemic therapy to best supportive/palliative-focused care.  \n\n- If imaging confirms extensive pseudomyxoma-like peritoneal disease without resectability, then adjust management from cytoreductive intent to symptom-directed systemic/supportive care.  \n\n- If CT/MRI or PET shows oligometastatic, potentially resectable lesions, then adjust management from systemic-only to consider surgical/locoregional MDT.  \n\n- If creatinine clearance falls <40 mL/min or major organ dysfunction emerges, then adjust management from full-dose multiagent therapy to modified/less intensive regimens.  \n\n- If patient prioritizes quality of life over survival extension, then adjust management from aggressive multi-line chemotherapy to minimal-burden palliative and hospice-focused approach.", "timestamp": "2026-01-18T00:15:56.057037"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Heavily pretreated recurrent high-grade serous ovarian carcinoma with progression on multiple platinum and non-platinum regimens; current line ≥5L.  \n\n- Recent sharp CA125 rise (21827, 2025-06-18) indicating biochemical progression after short-lived response to latest chemotherapy.  \n\n- Prior PARP inhibitor maintenance and prior anti-VEGF exposure limit expected benefit of reusing these targeted strategies.  \n\n- HRD and germline/somatic BRCA wildtype reduce rationale for further PARP inhibitor–based approaches.  \n\n- Missing: current ECOG/performance, detailed organ function (CBC, renal, hepatic), symptom burden/imaging to distinguish systemic therapy vs best supportive focus.", "timestamp": "2026-01-18T00:14:22.877904"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Systemic‑therapy decision requires contemporaneous ECOG, symptom burden, and full labs (CBC, renal, liver, nutrition); without these we cannot meaningfully weigh further chemotherapy versus best‑supportive‑care focus.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T00:14:50.428208"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T00:15:02.275536"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Prioritize goals‑of‑care discussion, documenting ECOG, detailed symptoms, and patient preferences to guide further systemic versus supportive care (currently unknown).  \n\n- Obtain updated labs (CBC, renal incl. CrCl, liver, electrolytes, nutrition) to assess fitness and safety for any further systemic therapy (currently unknown).  \n\n- Arrange contrast‑enhanced CT abdomen/pelvis and compare to prior imaging to characterize cystic disease, liver nodules, and hydronephrosis (details unknown).  \n\n- Convene MDT with surgery, interventional radiology, urology, and palliative care to plan symptom‑targeted procedures (drainage, obstruction relief, urinary decompression).  \n\n- Reassess non‑platinum, non‑PARPi systemic or clinical trial options only if performance status, labs, and patient goals support further treatment.", "timestamp": "2026-01-18T00:15:27.298206"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Large abdominal cystic lesions concerning for pseudomyxoma peritonei; size, exact distribution, and organ involvement need dedicated contrast CT report update. [@IMAGING_STUDIES|2025-06-28]\n\n- Multiple low-density hepatic nodules could represent metastases; require characterization with contrast-enhanced liver protocol CT or MRI. [@IMAGING_STUDIES|2025-06-28]\n\n- Mild right hydronephrosis suggests partial urinary tract obstruction; upstream ureteral level and cause need dedicated abdominopelvic imaging description. [@IMAGING_STUDIES|2025-06-28]\n\n- Disease trend versus prior imaging is unknown; require prior CT/MRI for comparison to assess progression or stability. [unknown/needs update]\n\n- PET/CT showed no abnormal FDG-avid disease in 2023; interval metabolic status since then is unknown. [@PET_IF_AVAILABLE|2023-12]", "timestamp": "2026-01-18T00:14:25.607004"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T00:14:52.627618"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T00:15:04.150959"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Large abdominal cystic lesions (possible pseudomyxoma) need contrast CT abdomen/pelvis with mapping for potential drainage or debulking planning. [@IMAGING_STUDIES|2025-06-28]\n\n- Low‑density hepatic nodules require contrast-enhanced liver imaging (CT/MRI) to confirm metastases versus benign lesions, if findings would alter palliation. [@IMAGING_STUDIES|2025-06-28]\n\n- Mild right hydronephrosis warrants definition of ureteric obstruction level and cause on contrast CT to guide stent/nephrostomy consideration. [@IMAGING_STUDIES|2025-06-28]\n\n- Disease trend is unknown; comparison with prior CT/MRI is needed only if it would influence symptom‑directed interventions. [unknown/needs update]\n\n- Repeat PET/CT is not routinely indicated; reserve for situations where additional metabolic information would clearly change local vs systemic strategy. [@PET_IF_AVAILABLE|2023-12]", "timestamp": "2026-01-18T00:15:35.748796"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Histology and IHC support high-grade serous carcinoma of tubo-ovarian origin involving widespread peritoneal surfaces and nodes [@CASE_VIEW|Unknown].  \n\n- Pathology shows low differentiation; formal FIGO stage not provided but distribution suggests advanced stage disease [@CASE_VIEW|Unknown].  \n\n- Somatic panel: HRD negative, BRCA1/2 wildtype; other mutations reported (ETV4, KMT2A, NF1, TP53) [@CASE_VIEW|Unknown].  \n\n- Biomarkers: PAX8+, WT1+, aberrant p53+, HER2 0; MSI, TMB, PD-L1 not reported [@CASE_VIEW|Unknown].  \n\n- Needed updates: exact pathology report dates, tumor sizes, FIGO stage assignment, full molecular report details (including MSI/TMB/PD-L1).", "timestamp": "2026-01-18T00:14:28.009071"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy.\",\"why\":\"missing\"},{\"target\":\"chair\",\"message\":\"Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T00:14:55.108067"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T00:15:05.955989"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Confirm no additional pathology/molecular reports (FIGO stage, MSI, TMB, PD‑L1, full panel dates) from outside institutions; currently unknown.  \n\n- Maintain diagnosis: recurrent high‑grade serous tubo‑ovarian carcinoma, low differentiated, BRCA/HRD wildtype, HER2 0 [@CASE_VIEW|Unknown].  \n\n- Document somatic mutations (ETV4, KMT2A, NF1, TP53) and HRD–/BRCA WT status clearly in the MDT record [@CASE_VIEW|Unknown].  \n\n- Reserve new biomarker testing (MSI/TMB/PD‑L1) for situations where results could realistically change palliative‑oriented management; presently unknown.  \n\n- No histologic evidence of alternative primary (e.g., gastrointestinal); PAX8+/WT1+/p53+ profile supports Müllerian origin [@CASE_VIEW|Unknown].", "timestamp": "2026-01-18T00:15:49.640585"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Prior FDG-PET/CT showed no hypermetabolic disease; no PET-visible metastases or recurrence at that time [@PET_CT|2023-12].  \n- Current CT describes abdominal cystic lesions and hepatic nodules, but their FDG avidity is unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \n- Right mild hydronephrosis is noted structurally; metabolic correlate on PET is unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \n- A repeat FDG-PET/CT could clarify metabolic activity of abdominal/hepatic lesions and up-/down-stage disease versus 2023 baseline.  \n- PET would meaningfully change suspicion of recurrence if new focal uptake appears in cystic, hepatic, or urinary-tract–adjacent regions.", "timestamp": "2026-01-18T00:14:30.428606"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T00:14:57.524512"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T00:15:07.367387"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.\n[R1T1 DELTA] ing): Current CT description (cystic lesions, liver nodules, hydronephrosis) lacks contrast-enhanced detail and size/trend, limiting decisions on palliative interventions (e.g., drainage, stenting, obstruction management). A dedicated contrast CT abdomen/pelvis with comparison to prior scans is needed if further procedures are being considered. | pathologist->oncologist(missing): Pathology confirms recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, HER2 0; MSI, TMB, PD‑L1 remain untested/undocumented and should be clarified only if results would realistically influence current palliative‑oriented strategy. | pathologist->chair(missing): Key pathology variables are still undocumented (FIGO stage, original report dates, full molecular including MSI/TMB/PD‑L1); please confirm whether any outside or updated pathology/molecular reports exist that are not yet in the record.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Prior FDG-PET/CT showed no hypermetabolic disease; no PET-detectable metastases or recurrence at that time [@PET_CT|2023-12].  \n- Current abdominal cystic lesions, hepatic nodules, and hydronephrosis lack PET correlation; metabolic activity remains unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \n- In this palliative context, repeat PET/CT is only justified if results would clearly change local versus systemic management decisions.  \n- PET would meaningfully upstage suspicion of recurrence if new focal FDG uptake appears in cystic, hepatic, or retroperitoneal regions.  \n- If future interventions are planned, consider PET/CT to distinguish metabolically active tumor from non-neoplastic cystic or treatment-related changes.", "timestamp": "2026-01-18T00:15:53.071748"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Today’s intent: disease is platinum‑resistant, heavily pretreated; shift focus toward symptom‑driven, QoL‑prioritized palliative strategy.  \\n- Before new systemic therapy: update ECOG, organ function (full labs, CrCl, liver tests), pain/ascites status, bowel obstruction details.  \\n- Clarify current symptoms from abdominal cysts, hydronephrosis, possible obstruction to prioritize surgery/intervention, stenting, drainage versus systemic therapy.  \\n- Reassess clinical‑trial eligibility (non‑platinum, non‑PARPi options) given HRD‑negative, BRCA‑wildtype, prior PARPi/anti‑VEGF exposure.  \\n- Early palliative care involvement for analgesia, bowel management, nutrition, and to align treatment intensity with patient/family goals.\",\"oncologist\":\"- Heavily pretreated recurrent high-grade serous ovarian carcinoma with progression on multiple platinum and non-platinum regimens; current line ≥5L.  \\n\\n- Recent sharp CA125 rise (21827, 2025-06-18) indicating biochemical progression after short-lived response to latest chemotherapy.  \\n\\n- Prior PARP inhibitor maintenance and prior anti-VEGF exposure limit expected benefit of reusing these targeted strategies.  \\n\\n- HRD and germline/somatic BRCA wildtype reduce rationale for further PARP inhibitor–based approaches.  \\n\\n- Missing: current ECOG/performance, detailed organ function (CBC, renal, hepatic), symptom burden/imaging to distinguish systemic therapy vs best supportive focus.\",\"radiologist\":\"- Large abdominal cystic lesions concerning for pseudomyxoma peritonei; size, exact distribution, and organ involvement need dedicated contrast CT report update. [@IMAGING_STUDIES|2025-06-28]\\n\\n- Multiple low-density hepatic nodules could represent metastases; require characterization with contrast-enhanced liver protocol CT or MRI. [@IMAGING_STUDIES|2025-06-28]\\n\\n- Mild right hydronephrosis suggests partial urinary tract obstruction; upstream ureteral level and cause need dedicated abdominopelvic imaging description. [@IMAGING_STUDIES|2025-06-28]\\n\\n- Disease trend versus prior imaging is unknown; require prior CT/MRI for comparison to assess progression or stability. [unknown/needs update]\\n\\n- PET/CT showed no abnormal FDG-avid disease in 2023; interval metabolic status since then is unknown. [@PET_IF_AVAILABLE|2023-12]\",\"pathologist\":\"- Histology and IHC support high-grade serous carcinoma of tubo-ovarian origin involving widespread peritoneal surfaces and nodes [@CASE_VIEW|Unknown].  \\n\\n- Pathology shows low differentiation; formal FIGO stage not provided but distribution suggests advanced stage disease [@CASE_VIEW|Unknown].  \\n\\n- Somatic panel: HRD negative, BRCA1/2 wildtype; other mutations reported (ETV4, KMT2A, NF1, TP53) [@CASE_VIEW|Unknown].  \\n\\n- Biomarkers: PAX8+, WT1+, aberrant p53+, HER2 0; MSI, TMB, PD-L1 not reported [@CASE_VIEW|Unknown].  \\n\\n- Needed updates: exact pathology report dates, tumor sizes, FIGO stage assignment, full molecular report details (including MSI/TMB/PD-L1).\",\"nuclear\":\"- Prior FDG-PET/CT showed no hypermetabolic disease; no PET-visible metastases or recurrence at that time [@PET_CT|2023-12].  \\n- Current CT describes abdominal cystic lesions and hepatic nodules, but their FDG avidity is unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \\n- Right mild hydronephrosis is noted structurally; metabolic correlate on PET is unknown/needs update [@IMAGING_CONTEXT|2025-06-28].  \\n- A repeat FDG-PET/CT could clarify metabolic activity of abdominal/hepatic lesions and up-/down-stage disease versus 2023 baseline.  \\n- PET would meaningfully change suspicion of recurrence if new focal uptake appears in cystic, hepatic, or urinary-tract–adjacent regions.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Recurrent high-grade serous tubo-ovarian carcinoma, BRCA/HRD wildtype, heavily pretreated (≥5th line) with progression after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF already used.  \n- Marked CA125 rise (21827, 18/06/2025) consistent with biochemical progression after short response to latest chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma peritonei), multiple low-density liver nodules (possible metastases), mild right hydronephrosis (partial obstruction). PET/CT in 12/2023 was negative; current metabolic activity unknown.  \n- Pathology confirms high‑grade serous carcinoma, widely peritoneal; molecular profile: HRD–, BRCA1/2 WT, other mutations (ETV4, KMT2A, NF1, TP53); HER2 0; MSI/TMB/PD‑L1 not reported.  \n- MDT inclination is toward symptom‑driven, QoL‑focused palliative strategy rather than aggressive systemic escalation.\n\nControversies:\n- Extent to which further systemic therapy (non‑platinum, non‑PARPi) offers meaningful benefit versus transitioning to best supportive/palliative care only.  \n- Need and timing for further imaging (contrast CT, liver protocol CT/MRI, repeat PET/CT) given heavy pretreatment and primarily palliative intent.  \n- Role and feasibility of interventional/surgical procedures (management of cystic disease, hydronephrosis, possible bowel obstruction) in a heavily pretreated patient.\n\nMissing Info:\n- Current performance status (ECOG), full symptom profile (pain, ascites, bowel obstruction/ileus, urinary symptoms) and impact on daily function/QoL.  \n- Up-to-date organ function: CBC, renal (including CrCl), liver tests, electrolytes; nutritional status.  \n- Detailed, up-to-date contrast-enhanced CT description of cystic lesions (size, distribution, organ involvement), hepatic lesions, and level/cause of hydronephrosis; comparison with prior imaging.  \n- Complete pathology/molecular report: FIGO stage, dates, full NGS including MSI, TMB, PD‑L1.  \n- Current clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Update clinical status: ECOG, comprehensive symptom review (pain, bowel, urinary, nutrition), physical exam.  \n- Obtain full labs (CBC, U&E, LFTs, coagulation, renal function/CrCl, nutritional markers).  \n- Repeat/complete imaging: contrast CT abdomen/pelvis with dedicated assessment of cystic lesions, liver nodules, hydronephrosis; consider liver protocol CT/MRI; use prior imaging for trend.  \n- Reassess need for PET/CT only if results would change management (e.g., clarify metabolic activity to guide local vs systemic approaches).  \n- Multidisciplinary review (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑directed interventions: obstruction management, possible drainage/debulking of symptomatic cysts, ureteric stenting/nephrostomy if clinically indicated.  \n- Evaluate realistic systemic options and clinical trials (non‑platinum, non‑PARPi) against performance status and patient’s goals.  \n- Early, structured palliative care involvement for analgesia, bowel regimen, nutritional support, and goals‑of‑care/advance care planning with patient and family.", "timestamp": "2026-01-18T00:14:37.930818"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Recurrent high-grade serous tubo-ovarian carcinoma, BRCA/HRD wildtype, heavily pretreated (≥5th line) with progression after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF already used.  \n- Marked CA125 rise (21827, 18/06/2025) consistent with biochemical progression after short response to latest chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma peritonei), multiple low-density liver nodules (possible metastases), mild right hydronephrosis (partial obstruction). PET/CT in 12/2023 was negative; current metabolic activity unknown.  \n- Pathology confirms high‑grade serous carcinoma, widely peritoneal; molecular profile: HRD–, BRCA1/2 WT, other mutations (ETV4, KMT2A, NF1, TP53); HER2 0; MSI/TMB/PD‑L1 not reported.  \n- MDT inclination is toward symptom‑driven, QoL‑focused palliative strategy rather than aggressive systemic escalation.\n\nControversies:\n- Extent to which further systemic therapy (non‑platinum, non‑PARPi) offers meaningful benefit versus transitioning to best supportive/palliative care only.  \n- Need and timing for further imaging (contrast CT, liver protocol CT/MRI, repeat PET/CT) given heavy pretreatment and primarily palliative intent.  \n- Role and feasibility of interventional/surgical procedures (management of cystic disease, hydronephrosis, possible bowel obstruction) in a heavily pretreated patient.\n\nMissing Info:\n- Current performance status (ECOG), full symptom profile (pain, ascites, bowel obstruction/ileus, urinary symptoms) and impact on daily function/QoL.  \n- Up-to-date organ function: CBC, renal (including CrCl), liver tests, electrolytes; nutritional status.  \n- Detailed, up-to-date contrast-enhanced CT description of cystic lesions (size, distribution, organ involvement), hepatic lesions, and level/cause of hydronephrosis; comparison with prior imaging.  \n- Complete pathology/molecular report: FIGO stage, dates, full NGS including MSI, TMB, PD‑L1.  \n- Current clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Update clinical status: ECOG, comprehensive symptom review (pain, bowel, urinary, nutrition), physical exam.  \n- Obtain full labs (CBC, U&E, LFTs, coagulation, renal function/CrCl, nutritional markers).  \n- Repeat/complete imaging: contrast CT abdomen/pelvis with dedicated assessment of cystic lesions, liver nodules, hydronephrosis; consider liver protocol CT/MRI; use prior imaging for trend.  \n- Reassess need for PET/CT only if results would change management (e.g., clarify metabolic activity to guide local vs systemic approaches).  \n- Multidisciplinary review (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑directed interventions: obstruction management, possible drainage/debulking of symptomatic cysts, ureteric stenting/nephrostomy if clinically indicated.  \n- Evaluate realistic systemic options and clinical trials (non‑platinum, non‑PARPi) against performance status and patient’s goals.  \n- Early, structured palliative care involvement for analgesia, bowel regimen, nutritional support, and goals‑of‑care/advance care planning with patient and family.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Recurrent high‑grade serous tubo‑ovarian carcinoma, BRCA/HRD wildtype, ≥5th‑line, progressed after multiple platinum and non‑platinum regimens; prior PARPi and anti‑VEGF used.  \n- CA125 markedly elevated (21827, 18/06/2025) after short‑lived response to last chemotherapy.  \n- Imaging: large abdominal cystic lesions (possible pseudomyxoma), low‑density liver nodules (possible mets), mild right hydronephrosis; PET/CT 12/2023 was negative, current metabolic status unknown.  \n- Pathology: high‑grade serous carcinoma with widespread peritoneal involvement; HRD–, BRCA WT, HER2 0, other mutations (ETV4, KMT2A, NF1, TP53); MSI/TMB/PD‑L1 not reported.  \n- MDT leaning toward symptom‑driven, QoL‑focused palliative strategy rather than further aggressive systemic therapy.\n\nControversies:\n- Whether further non‑platinum, non‑PARPi systemic therapy offers meaningful benefit versus best supportive care alone.  \n- Extent and timing of additional imaging (contrast CT, liver protocol CT/MRI, PET/CT) in a palliative context.  \n- Appropriateness and benefit–risk of surgical/interventional procedures for cystic disease, hydronephrosis, and possible bowel obstruction.\n\nMissing Info:\n- Current ECOG and detailed symptom burden (pain, ascites, bowel/urinary function, nutrition, QoL impact).  \n- Up‑to‑date labs: CBC, renal (incl. CrCl), liver tests, electrolytes, nutritional status.  \n- Current contrast‑enhanced CT with detailed mapping of cystic lesions, liver nodules, hydronephrosis level/cause, and comparison to prior imaging.  \n- Full pathology/molecular details including FIGO stage, report dates, MSI, TMB, PD‑L1.  \n- Clarified clinical trial eligibility for non‑platinum, non‑PARPi options.\n\nWorking Plan:\n- Reassess clinical status: ECOG, comprehensive symptom review, physical exam.  \n- Obtain full bloods (CBC, U&E, LFTs, coagulation, CrCl, nutritional markers).  \n- Update imaging: contrast CT abdomen/pelvis; consider liver protocol CT/MRI; compare with prior scans.  \n- Consider PET/CT only if likely to alter management (e.g., guide local vs systemic strategy).  \n- Multidisciplinary input (gyn/onc, surgery, IR, urology, palliative care) to prioritize symptom‑targeted interventions (obstruction relief, cyst drainage/debulking, ureteric stent/nephrostomy as appropriate).  \n- Re‑evaluate systemic options and clinical trials vs performance status and patient goals.  \n- Formal early palliative care involvement for analgesia, bowel management, nutrition, and goals‑of‑care discussions with patient/family.", "timestamp": "2026-01-18T00:14:44.182705"}]}, "trace_events": [{"ts": "2026-01-18T00:13:34.451587", "event": "pipeline_start", "payload": {"visit_time": "2023-07-01 15:38:50.183000", "meta_info": "410782197010112761"}}, {"ts": "2026-01-18T00:13:34.451898", "event": "case_fingerprint", "payload": {"case_fingerprint": "47b3c84d566f"}}, {"ts": "2026-01-18T00:13:34.751784", "event": "reports_loaded", "payload": {"lab_n": 0, "img_n": 0, "path_n": 0, "mut_n": 0, "cutoff_dt": "2023-07-02 15:38:50"}}, {"ts": "2026-01-18T00:13:34.812301", "event": "reports_selected", "payload": {"lab": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}}}, {"ts": "2026-01-18T00:14:09.660641", "event": "rag_query", "payload": {"query": "Recurrent platinum-resistant high-grade serous tubo-ovarian carcinoma with peritoneal, hepatic, appendiceal, colonic gutter and nodal involvement; PAX8+/WT1+/p53+, HER2 0, BRCA/HRD unknown; rising CA125, prior multiple lines including bevacizumab, PARPi; creatinine clearance ~53 mL/min."}}, {"ts": "2026-01-18T00:14:09.660649", "event": "rag_hits", "payload": {"topk": 5, "n": 5}}, {"ts": "2026-01-18T00:14:17.123283", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-18T00:15:53.071822", "event": "mdt_discussion_end", "payload": {"merged_chars": 3451}}, {"ts": "2026-01-18T00:15:53.072540", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-18T00:15:56.057084", "event": "final_output_end", "payload": {"final_output_chars": 849}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Global Guideline RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
